Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation
P Ljungman, R Brand, J Hoek… - Clinical Infectious …, 2014 - academic.oup.com
P Ljungman, R Brand, J Hoek, R de la Camara, C Cordonnier, H Einsele, J Styczynski…
Clinical Infectious Diseases, 2014•academic.oup.comThe use of a cytomegalovirus (CMV)–seropositive unrelated hematopoietic stem cell
transplant (HSCT) donor for a CMV-seronegative patient results in reduced overall survival.
The use of a CMV-seronegative unrelated HSCT donor for a seropositive patient results in
reduced overall survival after myeloablative conditioning.
transplant (HSCT) donor for a CMV-seronegative patient results in reduced overall survival.
The use of a CMV-seronegative unrelated HSCT donor for a seropositive patient results in
reduced overall survival after myeloablative conditioning.
The use of a cytomegalovirus (CMV)–seropositive unrelated hematopoietic stem cell transplant (HSCT) donor for a CMV-seronegative patient results in reduced overall survival. The use of a CMV-seronegative unrelated HSCT donor for a seropositive patient results in reduced overall survival after myeloablative conditioning.
Oxford University Press